Published in Arterioscler Thromb Vasc Biol on October 01, 2008
A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels. Nat Med (2017) 1.39
Expression of apolipoprotein C-III in McA-RH7777 cells enhances VLDL assembly and secretion under lipid-rich conditions. J Lipid Res (2010) 1.21
Investigations of apoC-III metabolism using stable isotopes: what information can you acquire and how can you interpret your results? J Lipid Res (2011) 0.77
Metabolsim of apoB and apoC lipoproteins in man: kinetic studies in normal and hyperlipoproteininemic subjects. J Lipid Res (1978) 1.53
Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest (2005) 1.49
Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism. J Clin Endocrinol Metab (2007) 1.38
Increased apoC-III production is a characteristic feature of patients with hypertriglyceridemia. Atherosclerosis (2004) 1.17
Metabolism of C-apolipoproteins: kinetics of C-II, C-III1 and C-III2, and VLDL-apolipoprotein B in normal and hyperlipoproteinemic subjects. J Lipid Res (1981) 1.02
Evidence for non-equilibrating pools of apolipoprotein C-III in plasma lipoproteins. J Lipid Res (1985) 0.96
Triglyceride-rich lipoprotein-associated apolipoprotein C-III production is stimulated by plasma free fatty acids in humans. Arterioscler Thromb Vasc Biol (2008) 0.95
Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome. Arterioscler Thromb Vasc Biol (2008) 0.92
Very low density lipoprotein. Removal of Apolipoproteins C-II and C-III-1 during lipolysis in vitro. J Biol Chem (1979) 0.87
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med (2010) 16.40
Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med (2010) 10.75
Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol (2007) 9.62
Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med (2011) 8.14
Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab (2008) 7.97
Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation (2011) 6.36
Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation (2006) 4.61
Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care (2007) 4.30
Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol (2007) 4.21
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J (2013) 3.58
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J (2011) 3.00
Inhibition of apolipoprotein B100 secretion by lipid-induced hepatic endoplasmic reticulum stress in rodents. J Clin Invest (2008) 2.58
Complexity in the secretory pathway: the assembly and secretion of apolipoprotein B-containing lipoproteins. J Biol Chem (2002) 2.48
Diabetic dyslipidemia. Endocrinol Metab Clin North Am (2006) 2.35
Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J (2015) 1.92
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol (2008) 1.88
Sample size determination. ILAR J (2002) 1.87
Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther (2007) 1.86
C-C chemokine receptor 2 (CCR2) regulates the hepatic recruitment of myeloid cells that promote obesity-induced hepatic steatosis. Diabetes (2010) 1.86
Faster plasma vitamin E disappearance in smokers is normalized by vitamin C supplementation. Free Radic Biol Med (2005) 1.85
Prevention or delay of type 2 diabetes. Diabetes Care (2004) 1.73
Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial. Diabetes Care (2013) 1.71
Adipocyte signaling and lipid homeostasis: sequelae of insulin-resistant adipose tissue. Circ Res (2005) 1.68
Lipid peroxidation and oxidant stress regulate hepatic apolipoprotein B degradation and VLDL production. J Clin Invest (2004) 1.67
Aberrant hepatic expression of PPARgamma2 stimulates hepatic lipogenesis in a mouse model of obesity, insulin resistance, dyslipidemia, and hepatic steatosis. J Biol Chem (2006) 1.63
Short sleep duration as a risk factor for hypercholesterolemia: analyses of the National Longitudinal Study of Adolescent Health. Sleep (2010) 1.59
CCR5 plays a critical role in obesity-induced adipose tissue inflammation and insulin resistance by regulating both macrophage recruitment and M1/M2 status. Diabetes (2012) 1.56
Autonomic nervous system influences on QT interval in normal subjects. J Am Coll Cardiol (2002) 1.53
Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance. Trends Endocrinol Metab (2011) 1.53
Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest (2005) 1.49
Improved diabetic control in advanced heart failure patients treated with left ventricular assist devices. Eur J Heart Fail (2010) 1.49
Lipoprotein(a): an elusive cardiovascular risk factor. Arterioscler Thromb Vasc Biol (2004) 1.48
Methyl isocyanate exposure and growth patterns of adolescents in Bhopal. JAMA (2003) 1.39
Overexpression of the tumor autocrine motility factor receptor Gp78, a ubiquitin protein ligase, results in increased ubiquitinylation and decreased secretion of apolipoprotein B100 in HepG2 cells. J Biol Chem (2003) 1.37
Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease. Am J Cardiol (2008) 1.35
Specific loss of brain ABCA1 increases brain cholesterol uptake and influences neuronal structure and function. J Neurosci (2009) 1.31
Studies in humans using deuterium-labeled alpha- and gamma-tocopherols demonstrate faster plasma gamma-tocopherol disappearance and greater gamma-metabolite production. Free Radic Biol Med (2005) 1.28
Activation of ER stress and mTORC1 suppresses hepatic sortilin-1 levels in obese mice. J Clin Invest (2012) 1.28
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res (2008) 1.27
Ins and outs modulating hepatic triglyceride and development of nonalcoholic fatty liver disease. Gastroenterology (2006) 1.27
Inhibition of Notch uncouples Akt activation from hepatic lipid accumulation by decreasing mTorc1 stability. Nat Med (2013) 1.23
Understanding interdisciplinary health sciences collaborations: a campus-wide survey of obesity experts. AMIA Annu Symp Proc (2008) 1.22
Chylomicron- and VLDL-derived lipids enter the heart through different pathways: in vivo evidence for receptor- and non-receptor-mediated fatty acid uptake. J Biol Chem (2010) 1.22
Altered hepatic lipid metabolism in C57BL/6 mice fed alcohol: a targeted lipidomic and gene expression study. J Lipid Res (2011) 1.21
Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol (2014) 1.20
Scavenger receptor class B type I mediates the selective uptake of high-density lipoprotein-associated cholesteryl ester by the liver in mice. Arterioscler Thromb Vasc Biol (2004) 1.19
Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants. Diabetes Care (2012) 1.14
Apolipoprotein CIII: 42 years old and even more interesting. Arterioscler Thromb Vasc Biol (2011) 1.14
Whole-body insulin resistance in the absence of obesity in FVB mice with overexpression of Dgat1 in adipose tissue. Diabetes (2005) 1.13
Regulation of hepatic apolipoprotein B-lipoprotein assembly and secretion by the availability of fatty acids. I. Differential response to the delivery of fatty acids via albumin or remnant-like emulsion particles. J Biol Chem (2004) 1.10
Transplacental delivery of retinoid: the role of retinol-binding protein and lipoprotein retinyl ester. Am J Physiol Endocrinol Metab (2004) 1.10
DGAT1 deficiency decreases PPAR expression and does not lead to lipotoxicity in cardiac and skeletal muscle. J Lipid Res (2011) 1.09
Intestinal DGAT1 deficiency reduces postprandial triglyceride and retinyl ester excursions by inhibiting chylomicron secretion and delaying gastric emptying. J Lipid Res (2012) 1.06
{alpha}-Tocopherol disappearance is faster in cigarette smokers and is inversely related to their ascorbic acid status. Am J Clin Nutr (2005) 1.06
Protective effect of apolipoprotein E2 on coronary artery disease in African Americans is mediated through lipoprotein cholesterol. J Lipid Res (2006) 1.05
Posttranscriptional control of the expression and function of diacylglycerol acyltransferase-1 in mouse adipocytes. J Biol Chem (2002) 1.02
Saturated fat-rich diet enhances selective uptake of LDL cholesteryl esters in the arterial wall. J Clin Invest (2005) 1.01
Scavenger receptor CD36 mediates uptake of high density lipoproteins in mice and by cultured cells. J Lipid Res (2011) 1.01
Hepatic ATP-binding cassette transporter A1 is a key molecule in high-density lipoprotein cholesteryl ester metabolism in mice. Arterioscler Thromb Vasc Biol (2006) 1.01
Comparison of monounsaturated fat with carbohydrates as a replacement for saturated fat in subjects with a high metabolic risk profile: studies in the fasting and postprandial states. Am J Clin Nutr (2007) 1.01
Effectiveness of combined statin plus omega-3 fatty acid therapy for mixed dyslipidemia. Am J Cardiol (2008) 0.99
Effect of gender on the manifestations of celiac disease: evidence for greater malabsorption in men. Scand J Gastroenterol (2005) 0.97
Cholesterol-lowering benefits of oat-containing cereal in Hispanic americans. J Am Diet Assoc (2005) 0.97
Apo[a] size and PNR explain African American-Caucasian differences in allele-specific apo[a] levels for small but not large apo[a]. J Lipid Res (2006) 0.96
Lipoprotein metabolism in chronic renal insufficiency. Pediatr Nephrol (2007) 0.96
The role of acyl-CoA:diacylglycerol acyltransferase (DGAT) in energy metabolism. Ann Med (2004) 0.94
Apolipoprotein [a] genotype influences isoform dominance pattern differently in African Americans and Caucasians. J Lipid Res (2002) 0.93
PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era. Curr Opin Lipidol (2015) 0.93
Different fatty acids inhibit apoB100 secretion by different pathways: unique roles for ER stress, ceramide, and autophagy. J Lipid Res (2011) 0.92
Change in lipid profile in celiac disease: beneficial effect of gluten-free diet. Am J Med (2006) 0.91
The lymphocytic infiltration in calcific aortic stenosis predominantly consists of clonally expanded T cells. J Immunol (2007) 0.91
Adipose tissue distribution after weight restoration and weight maintenance in women with anorexia nervosa. Am J Clin Nutr (2009) 0.90
Effects of a 1,3-diacylglycerol oil-enriched diet on postprandial lipemia in people with insulin resistance. J Lipid Res (2007) 0.90
Endothelial function in individuals with coronary artery disease with and without type 2 diabetes mellitus. Metabolism (2010) 0.88
Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects. J Clin Invest (2015) 0.88
Measurement of apo(a) kinetics in human subjects using a microfluidic device with tandem mass spectrometry. Rapid Commun Mass Spectrom (2013) 0.86
Measures of postprandial lipoproteins are not associated with coronary artery disease in patients with type 2 diabetes mellitus. J Lipid Res (2009) 0.86
Effects of antisense-mediated inhibition of 11β-hydroxysteroid dehydrogenase type 1 on hepatic lipid metabolism. J Lipid Res (2011) 0.85
Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia. J Lipid Res (2005) 0.85
Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus. Expert Opin Pharmacother (2011) 0.84
Apolipoprotein B secretion is regulated by hepatic triglyceride, and not insulin, in a model of increased hepatic insulin signaling. Arterioscler Thromb Vasc Biol (2011) 0.84
Translocation efficiency of apolipoprotein B is determined by the presence of beta-sheet domains, not pause transfer sequences. J Biol Chem (2006) 0.84
Effects of lipoprotein lipase and statins on cholesterol uptake into heart and skeletal muscle. J Lipid Res (2006) 0.83
The apolipoprotein(a) gene: linkage disequilibria at three loci differs in African Americans and Caucasians. Atherosclerosis (2008) 0.82
Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trial. Diabetes Care (2012) 0.81